Orexins are neuropeptides that are localized in neurons within the lateral hypothalamus and regulate feeding behavior. The lateral hypothalamus plays an important role in not only feeding but also in the central regulation of gut function. Along this line, accumulating evidence has shown that orexins act in the central nervous system to regulate gastrointestinal functions. The purpose of this review is to summarize recent relevant fi ndings on brain orexins and the digestive system, and discuss the pathophysiological roles of these peptides. Centrally administered orexin or endogenously released orexin in the brain potently stimulates gastric acid secretion in rats. The vagal cholinergic pathway is involved in the orexin-induced stimulation of acid secretion. Because of its stimulatory action on feeding, it can be hypothesized that orexin in the brain is a candidate mediator of cephalic phase gastric secretion. In addition, brain orexin may be involved in the development of depression and functional gastrointestinal disorders, which are frequently accompanied by inhibition of gut function, because lack of orexin activity might cause the inhibition of gastric physiological processes and evoke a depressive state. These lines of evidence suggest that orexin in the brain is a potential molecular target for treatment of functional gastrointestinal disorders.
Introduction
Approximately 10 years ago, the orexins, also called hypocretins, were fi rst described as a pair of neuropeptides expressed by a specifi c population of neurons in the lateral hypothalamic area (LH), a region of the brain implicated in feeding, arousal, and motivated behavior. 1, 2 More than 1500 papers on these peptides have already been published. Orexin neurons project widely to numerous brain regions, and the orexinergic system is involved in not only feeding behavior but also sleep/wakefulness and energy homeostasis. [3] [4] [5] [6] [7] In addition, accumulating evidence indicates that orexin in the brain plays a role in the central regulation of gut function through the autonomic nervous system. The purpose of the present review is to present the view that orexin in the brain plays a role as a trigger molecule that drives the process of cephalic phase gut stimulation. We also propose the hypothesis that lack of orexin activity in the brain might contribute to the development of functional gastrointestinal disorders, which are frequently associated with the inhibition of gut function.
Distribution of orexin neurons and receptors in the brain
Orexins A and B/hypocretins 1 and 2 were discovered simultaneously by two independent research groups and thus separately named. 1, 2 The orexins were discovered by Sakurai et al. 1 during a search for endogenous ligands that activate orphan G protein-coupled receptors. Independently, de Lecea et al., 2 using directional tag polymerase chain reaction subtraction, identifi ed a hypothalamic-specifi c mRNA encoding a precursor protein that they called prepro-hypocretin, and they predicted that processing of this prepro-peptide would yield two peptides, hypocretins 1 and 2. Orexins A and B are coded from the same prepro-mRNA, and preproorexin neurons are located in and adjacent to the LH. 1 Sakurai et al. 1 also identifi ed the amino acid sequences of the receptors for the two peptides. OX 1 R was shown to bind orexin A with high affi nity and orexin B with 100-to 1000-fold lower affi nity. Another receptor, OX 2 R, identifi ed by searching database entries with the OX 1 R sequence, was shown to have equally high affi nity for both peptides. Thus, they concluded that OX 2 R was a nonselective receptor for both orexin A and orexin B, and that OX 1 R was selective for orexin A (Table 1) . Immunohistochemical and in situ hybridization studies have shown that orexin-producing neurons in the brain are restricted to a few nuclei in the hypothalamus, the perifornical nucleus, the LH, and the dorsomedial hypothalamic nucleus.
1,2 Despite their highly restricted origin, orexin nerve fi bers are identifi ed widely throughout the central nervous system. [3] [4] [5] [6] In parallel with the diffuse orexin-containing projections from the LH, orexin receptors are expressed in a pattern consistent with orexin nerve fi bers. [8] [9] [10] [11] Table 2 summarizes the distribution of specifi c orexin receptors in the brain in accordance with this evidence. As demonstrated, orexin receptors are site-specifi cally localized in the brain, suggesting a physiological role of each orexin receptor in relation to site-specifi c functions. It has been furthermore speculated that the widespread projections of the orexin neurons throughout the neuroaxis suggest that activation of orexin circuits probably modulates a variety of biological systems.
Orexins and feeding
Because of their strong localization in the LH, orexins might play a role in physiological functions associated with this brain site. Since the LH regulates feeding behavior, 12, 13 Sakurai et al. 1 examined the effect of orexins on food intake and showed that intracerebroventricular administration of orexins potently stimulates food consumption in rats. They have also shown that fasting upregulates prepro-orexin mRNA levels, indicating that orexins may be involved in the regulation of feeding behavior. In addition, Yamada et al. 14 have demonstrated that intracisternal but not intraperitoneal injection of orexin antibody dose-dependently suppresses feeding in rats, suggesting that immunoneutralization of endogenous orexins in the brain reduces food intake. In other words, endogenous brain orexin may have a physiologically relevant action on feeding behavior. When orexin is injected into several specifi c brain areas such as the hypothalamic arcuate, perifornical, lateral, dorsomedial, and paraventricular nuclei, the ventral tegmental area, and the nucleus accumbens, [15] [16] [17] [18] [19] [20] [21] food intake is increased, suggesting that these areas of the brain may be sites of action of orexin to stimulate food intake. Behavioral observation studies also indicate that central orexin A administration induces feeding-related activities such as grooming, burrowing, and rearing, 15 further supporting the hypothesis that orexins are implicated in the central regulation of feeding behavior.
Stimulation of acid secretion by intracisternal injection of orexin A
In addition to feeding behavior, earlier investigators have demonstrated that the LH contributes to the central regulation of gastric secretion. 22 These fi ndings led them to speculate that orexins in the brain may play a role in not only feeding but also gastric secretion. Intracisternal injection of orexin A increased the volume Distribution of orexin receptors in the brain is based on previous reports [8] [9] [10] [11] of gastric juice and stimulated gastric acid output in a dose-dependent manner in pylorus-ligated conscious rats. In contrast, intraperitoneal administration of orexin A did not stimulate gastric secretion, suggesting that orexin A acts in the central nervous system to stimulate gastric secretion. 23 A number of peptides and chemicals tested failed to stimulate acid secretion. 22, [24] [25] [26] [27] In fact, among these, only thyrotropin-releasing hormone (TRH) has been convincingly established by several groups of investigators to be a central stimulant of gastric acid secretion. 22 This evidence suggests that orexin A in the brain should be considered to be a specifi c molecule that is capable of stimulating gastric acid secretion. The doses to stimulate acid secretion are the same size as or smaller than those injected by Sakurai et al. 1 to stimulate food consumption in rats. The evidence that orexin A stimulates both gastric secretion and food intake in the same dose range is notable because both responses to orexin A might be triggered by a common mechanism. Electrical stimulation of the LH increases gastric acid secretion. 28, 29 Earlier studies showed that lesions or anesthetization of the LH attenuates the increase in gastric acid secretion caused by the peripheral administration of hypoglycemic agents. [30] [31] [32] Thus, LH plays a vital role in acid secretion, especially in response to the hunger sensation, which is probably induced by lowering blood glucose levels. However, little is known about the mechanisms by which stimulation of LH neurons increases gastric acid production on a molecular/neurotransmitter basis. Because of the striking localization of orexin-containing neurons in the LH and some adjacent areas, 1 and the stimulation of gastric acid by central orexin A, we speculate that the release of orexin A in the terminal nerve endings of LH neurons may activate the neuronal system to stimulate acid secretion. Thus, orexin A may function as an efferent signal from the LH neurons to increase gastric acid secretion.
Involvement of OX 1 receptor in acid stimulation by orexin A
The stimulation of gastric acid secretion is seen after intracisternal injection of orexin A but not of orexin B, suggesting that orexin A stimulates acid production in a specifi c manner. Because the characterization of the orexin receptors indicated that OX 1 R is selective for orexin A while OX 2 R is nonselective for both orexin A and B, the fi nding that centrally administered orexin A but not orexin B stimulates acid secretion 23 may indicate that OX 1 R mediates orexin A-induced acid stimulation. Orexin A is a peptide consisting 33 amino acids with two intrachain disulfi de bonds, namely Cys6-Cys12 and Cys7-Cys14, whereas orexin B is a peptide containing 28 amino acids without any disulfi de bonds (Table 1) . To further characterize the structure-activity relationship of orexin A to stimulate gastric acid secretion, orexin A-related peptides with modifi ed disulfi de bonds [orexin A (15) (16) (17) (18) (19) (20) (21) (22) (23) (24) (25) (26) (27) (28) (29) (30) (31) (32) (33) ] were constructed and their activity on receptor activation in vitro or stimulatory action of acid secretion in vivo was evaluated. 33 Intracisternal injection of orexin A but not of orexin B or orexin A(15-33), which does not contain the two disulfi de bonds, stimulated gastric acid secretion in pylorus-ligated conscious rats. The ability to stimulate gastric acid output was less in three alanine-substituted orexin A molecules, [Ala 6, 12 ]orexin A, [Ala 7, 14 ]orexin A and [Ala 6, 7, 12, 14 ]orexin A, than in orexin A. The orexin-induced calcium increase was measured in CHO-K1 cells expressing OX 1 R or OX 2 R. In vitro studies showed that orexin A induced a transient increase in [Ca 2+ ]i in CHO-K1/OX 1 R cells in a dose-dependent manner. Half maximal effective (EC 50 ) values for OX 1 R of orexin A, orexin B, and orexin-A(15-33) were 0.068, 0.69, and 4.1 nM, respectively, suggesting that peptides containing no disulfi de bonds have a lower potency for OX 1 R. Agonistic activity for OX 1 R of the three orexin A analogs with modifi cation of one or both disulfi de bonds was signifi cantly reduced compared with that of orexin A. EC 50 values for OX 2 R of orexin A and orexin B were almost equal, but potency for the receptor of orexin A (15-33) and the three alanine-substituted orexin A molecules was less than that of orexin A. A signifi cant inverse relationship between gastric acid output and EC 50 values for OX 1 R but not OX 2 R was observed. These results suggest that orexin A-induced acid stimulation requires OX 1 R activation and that disulfi de bonds in orexin A may play a key role in the receptor activation.
Vagal-dependent mechanism of acid stimulation by central orexin A
The vagal system is involved in the stimulation of acid secretion by orexin A because atropine or surgical vagotomy completely blocks acid stimulation by intracisternal orexin A. 23 A vagal-dependent mechanism of the stimulation of acid secretion by central orexin A is also supported by the evidence, described below, that the dorsal motor nucleus (DMN) of the vagus in the medulla oblongata is the site of action of orexin A to stimulate gastric acid.
DMN as the site of action in the brain to stimulate acid secretion
Cells innervating the stomach through the vagus nerve are located in the DMN in the medulla oblongata. 34, 35 Since intracisternally injected orexin A-induced acid production is mediated by the vagus nerve, 23 the DMN neurons projecting their axon terminals to the stomach should be activated by the injection of orexin A into the cisterna magna. Although orexin-immunoreactive neurons are located only in the hypothalamus, 1 orexinimmunoreactive fi bers are widely distributed in the central nervous system, including in the DMN. 4, 6, 14, 36 The fact that orexin-immunoreactive fi bers are identifi ed in the DMN and that the DMN neurons receive axon terminals from the LH neurons 37, 38 may support the idea that the site of action of intracisternally injected orexin A to induce acid production is on the DMN neurons. Results of immunohistochemical studies indicate that most DMN neurons in the rat express orexin receptors, with OX 1 R found in greater abundance than OX 2 R. 39 In addition, Krowicki et al. 39 showed, by combining immunostaining for OX 1 R with retrograde labeling of neurons following injection of fl uorescently tagged cholera toxin into the gastric wall, that OX 1 R is expressed in most preganglionic vagal motor neurons that innervate the stomach. These neuroanatomical studies indicate that orexin A is capable to binding to OX 1 R on DMN neurons innervating the stomach. Moreover, recordings obtained from rat medullary slices revealed that orexin directly depolarizes a fraction of DMN neurons, including some that were identifi ed as preganglionic parasympathetic neurons based on their retrograde labeling following intraperitoneal administration of Fluorogold. 40 Grabauskas and Moises 41 have demonstrated using whole-cell recordings obtained from DMN neurons in rat brainstem slices that orexins act preferentially within the DMN to directly excite DMN neurons that project to the stomach. These electrophysiological studies together with the neuroanatomical evidence described above and the pharmacological results suggest that endogenous orexin A from descending hypothalamic projections into the DMN activates OX 1 R on the DMN, followed by stimulation of the vagal fl ow that presumably causes the increase in acid output from the stomach. The fi nding by Krowicki et al. 39 that microinjection of orexins into the DMN increases intragastric pressure and antral motility in rats indicates that orexins indeed act in the DMN to stimulate gastric function.
Endogenous orexin A in the brain plays a role in the stimulation of acid secretion
The blockade of receptors by selective antagonists is a commonly used approach to assess the physiological role of endogenous peptides. While intraperitoneal administration of SB334867, a specifi c OX 1 R anatagonist, [42] [43] [44] [45] by itself did not change gastric acid secretion in pylorus-ligated conscious rats, pretreatment with SB334867 completely blocked the stimulated acid output by intracisternal orexin A but not by TRH, suggesting that SB334867 specifi cally blocked the action of orexin A in the brain. 46 2-Deoxy-D-glucose (2-DG) has been used as a tool for central activation of the vagal pathway. When administered peripherally, 2-DG acts in the brain, especially in the hypothalamus, to increase vagal tone, thereby stimulating gastric acid secretion. 47, 48 2-DG-induced stimulation of gastric acid output was signifi cantly blocked by pretreatment with intraperitoneal administration of SB334867, suggesting therefore that endogenously released orexin A in the brain indeed plays a vital role in central regulation of gastric secretion and that OX 1 R is involved in the acid stimulation by endogenously released orexin A. Some reports have shown that hypoglycemia activates orexin A neurons. Cai et al. 49 have demonstrated that insulin-induced hypoglycemia stimulates c-fos expression in orexin A neurons in the LH in rats. 2-DG is also known to inhibit glucose utilization (glucoprivation) and cause intracellular glucopenia. 50 Briski and Sylvester 51 examined the effect of 2-DG on c-fos expression in neurons containing orexin A in the hypothalamus and demonstrated that a large majority of orexin A neurons in the LH were immunostained for c-fos, while orexin A neurons expressed negligible c-fos immunoreactivity following vehicle administration, suggesting that central glucopenia induced by 2-DG activates orexin A neurons in the LH. These studies of c-fos expression may support the inference that 2-DG activates the hypothalamic orexin A system, followed by stimulation of gastric secretion through the vagal system.
Cephalic-phase acid stimulation by central orexin A
The cephalic phase of gastrointestinal secretion, which occurs in response to the sight, smell, taste, and anticipation of feeding, produces a coordinated secretory response that primes the gut to assist digestion of the impending meal. The most important component of the cephalic-phase responses is gastric acid secretion, as fi rst characterized by Pavlov. 52 The cephalic phase of gastric secretion is important because it primes the secretory capability of the gut, increasing the effi ciency of the subsequent gastric and intestinal phases of secretion that occur in response to a meal. Despite this, little is known about the precise molecular mechanism of cephalic-phase stimulation. Although TRH is the only established neuropeptide that acts in the brain to stimulate gastric secretion, 22 TRH does not initiate feeding behavior. 53, 54 In addition to the powerful effect on feeding behavior of orexins, 1 the evidence that orexin A has a potent stimulatory effect on the major secretory component of the cephalic phase makes orexin A an important candidate as a mediator of the cephalic-phase secretory response to feeding (Fig. 1) . As described, endogenous orexin A in the brain may play a vital role in 2-DG-induced acid secretion because an OX 1 R antagonist, SB334867, blocks the stimulation of gastric acid by 2-DG. 45 Since 2-DG induces central glucoprivation as a hunger state, the evidence further supports the inference that orexin A may be an important molecule that triggers the cephalic-phase gastric acid secretion. The importance of the vagus in conveying the neural impulses that mediate cephalic-phase gastric secretion has been recognized. 55 The vagal-dependent stimulation of gastric secretion of orexin A furthermore supports our speculation that orexin A plays a key role in cephalic-phase gastric secretion. The concept that the same peptide responsible for activating feeding also triggers an appropriate preparatory secretory response is attractive because it suggests the sort of simple economy that characterizes so many biological systems.
The LH, the so-called subthalamic locomotor region (SLR), is a major driver of the initiation of locomotion. 56 Efferent signals from the SLR are considered to evoke locomotion by activating neurons in the mesencephalic locomotor region (MLR) and the medullary reticular formation. The location of the SLR largely corresponds to the perifornical lateral hypothalamic area, the origin of orexinergic neurons. Because there are dense orexinergic projections to the midbrain, Takakusaki et al. 57 injected orexin A into midbrain areas, including the MLR and the pedunculopontine tegmental nucleus (PPN), in decerebrate cats. They demonstrated that microinjections of orexin A into the PPN/MLR enhanced the level of postural muscle tone and facilitated locomotor movements. Locomotion is one expression of emotional motor behaviors, including attack, defense, feeding, and searching. 58 Starting locomotion, accompanied by the sequence of seeking and acquiring food, is the initial step in feeding behavior. 59 The above evidence may support our hypothesis that orexin A is a vital molecule in the brain that triggers cephalic-phase stimulation such as food intake and the appropriate preparatory secretory responses.
Gastric motility and pancreatic secretion by brain orexin
Several studies have demonstrated that centrally injected orexin changes gastric motility. Kobashi et al. 60 examined the effects of the intracisternal administration of orexin A on gastric motility in rats and found that orexin induced relaxation of the proximal stomach lasting for more than 30 min. Phasic contractions in the distal stomach were also facilitated in response to orexin, but facilitation in the distal stomach was not Schematic illustration of our hypothesis that orexin might be a trigger molecule involved in cephalicphase gut secretion. The cephalic phase of gastrointestinal secretion, which occurs in response to the sight, smell, taste, and anticipation of feeding, produces a coordinated secretory response through a vagal pathway. Orexin neurons in the lateral hypothalamus (LH) project their terminals to the dorsal motor nucleus (DMN). DMN neurons stimulated by orexin increase gastric acid secretion, gastric motility, and pancreatic secretion through the vagus nerve. Since orexin plays a vital role in the stimulation of feeding behavior, orexin in the brain may be a trigger molecule to complete the process of feeding and gut secretion in response to the cephalic-phase stimulation seen in vagotomized animals. Relaxation of the proximal stomach was identifi ed in vagotomized animals, but the magnitude of relaxation was signifi cantly smaller than that in intact animals, suggesting that central orexin facilitates distal stomach motility and relaxation of the proximal stomach via the vagus nerve. 60 Since relaxation in the proximal stomach and enhanced motility in the distal stomach are observed during feeding, 61 the gastric motility change evoked by central orexin A suggests that orexin A may function to coordinate gastrointestinal motility during feeding. From this point of view, it should be noted that orexin A is a trigger molecule that plays a vital role in cephalic-phase stimulation, as described above. In addition, Krowicki et al. 39 have shown that microinjection of orexins into the DMN increases intragastric pressure and antral motility in rats, indicating that orexins in the DMN stimulate gastric motor function. Thus, orexin acts in the DMN to stimulate not only gastric acid secretion but also gastric motility.
Miyasaka et al. 62 have demonstrated that intracerebroventricular injection of orexin A signifi cantly stimulates pancreatic exocrine secretion through the vagus nerve in rats. The stimulation of pancreatic secretion by central orexin A was seen after pretreatment with omeprazole, indicating that the pancreatic stimulatory action by orexin A is independent of gastric acid secretion. Thus, orexin A acts in the brain to stimulate not only gastric but also pancreatic secretion through the vagal system. Wu et al. 63 have recorded vagal pancreatic efferent nerve activities in anesthetized rats. Insulininduced hypoglycemia stimulated an increase in pancreatic efferent nerve fi ring, whereas microinjection of the OX 1 R antagonist SB334867 into the DMN inhibited pancreatic nerve fi ring evoked by insulin-induced hypoglycemia by 56%. In contrast, injection of orexin A into the DMN elicited a 30-fold increase in pancreatic nerve fi ring. From these results, they suggested that hypoglycemia activates release of orexin from the LH, which acts on DMN neurons to stimulate pancreatic efferent nerve activities, thereby stimulating pancreatic functions. Because pancreatic secretion is an important component of cephalic-phase gut secretion, the evidence that the stimulation of pancreatic secretion by central orexin A may further support our hypothesis that orexin A may be a trigger molecule involved in cephalic-phase stimulation.
Gastroprotection by orexin A
The effect of central orexin A on the development of gastric mucosal damage evoked by ethanol was examined in rats. Intracisternal but not intraperitoneal injection of orexin A signifi cantly inhibited the severity of gastric mucosal damage by 70% ethanol in a dosedependent manner, suggesting that orexin A acts in the brain to prevent ethanol-induced gastric mucosal damage. 64 The antiulcer action was observed in rats after central administration of orexin A but not after orexin B, indicating that the action is mediated through OX 1 R. The gastroprotective action of central orexin A was blocked by pretreatment with atropine, N w -nitro-Larginine methylester (L-NAME), or indomethacin, suggesting that orexin A acts on OX 1 R in the brain to exert a gastroprotective action against ethanol through vagal muscarinic system, nitric oxide, and prostaglandin pathways. The involvement of nitric oxide (NO) in the orexin pathway has been reported. According to Farr et al., 65 subcutaneous injection of L-NAME, an inhibitor of NO synthase, blocked the orexin A-induced increase in food intake by rats, and orexin A failed to increase the food intake of the NO synthase knockout mice. They further demonstrated that L-NAME drastically inhibited NO synthase activity in the hypothalamus, suggesting that NO in the brain plays a vital role in orexin A-induced food consumption. In addition, Zheng et al. 66 have demonstrated that as many as 20% of hypothalamic orexin neurons project to the dorsal vagal complex, including the DMN neurons in the medulla, some of which are in close anatomical apposition with NO synthase-immunoreactive neurons, indicating that NO in the brain might regulate the tone of the vagal system. Thus, NO in the brain may be involved in orexin A-induced central regulation of gastrointestinal functions through the vagal system. In any event, the evidence that orexin A in the brain possesses gastroprotective action against ethanol suggests that orexin A might protect the gastric mucosa from possible injury during food intake with alcohol.
Depression, functional gastrointestinal disorders, and orexin
Immunohistochemical and electrophysiological studies have shown that orexin neurons in the lateral hypothalamus regulate monoaminergic and serotonergic neurons in the brainstem. [67] [68] [69] [70] Since depression is associated with a lack of monoaminergic or serotonergic activity in the brain, 71 orexins may be involved in the pathology of depression. Several studies have investigated the relationship between orexin in the brain and depression. Wistar-Kyoto (WKY) rats exhibit depressive characteristics and patterns of sleep disruption similar to that observed in depressed human patients. 72 Allard et al. 73 have shown by immunocytochemistry that WKY rats have 18% fewer orexin A-positive neurons and show a 15% decrease in the average neuronal soma size of orexin A-producing cells in the hypothalamus compared with control rats, suggesting that a reduced number or size of hypothalamic orexinergic neurons may be involved in the depressive characteristics of WKY rats. Lutter et al. 74 have demonstrated that 10 days of calorie restriction, corresponding to a 20%-25% weight loss, causes a marked antidepressant-like response in two rodent models of depression and that this response is dependent on hypothalamic orexin, suggesting that orexin plays a role in mediating the reduction of depression-like symptoms induced by calorie restriction. These fi ndings in rodent models suggest that inhibition of hypothalamic orexinergic projection might contribute to the development of depression. In addition, Brundin et al. 75 measured orexin A in the cerebrospinal fl uid (CSF) of 66 patients with major depressive disorder, dysthymia, or adjustment disorder after a suicide attempt. CSF levels of orexin A were significantly lower in patients with major depressive disorder than in those with adjustment disorder or dysthymia. All these lines of evidence suggest that hypothalamic orexin may be implicated in the depressive state.
Functional gastrointestinal disorders (FGIDs) comprise a major portion of gastrointestinal practice and primary care, and are associated with signifi cant absenteeism from work, impaired health-related quality of life, and increased medical costs. 76 Brain-gut interactions play an important role in the pathophysiology of FGID. Possibly via the brain-gut axis, psychosocial factors, including depression, infl uence gut physiology, the symptom experienced, health behavior, and outcome. 76 In other words, depression is closely associated with the pathophysiology of FGIDs, which are characterized by disturbance of gastrointestinal functions. Because lack of orexin activity might cause inhibition of gastric physiological processes, as shown by us and other investigators as described above, 23, 33, 39, 46, 60 and evoke a depressive state, [73] [74] [75] decreased activity of orexin in the brain might play a vital role in the mechanism of FGIDs, which are frequently associated with both the inhibition of gut function and depression. These fi ndings allow us to speculate that orexin in the brain is a possible molecular target for the treatment of FGID.
Interaction with ghrelin
Accumulating evidence suggests that ghrelin, a peptide produced in the stomach, plays a key role in feeding behavior and several gastrointestinal functions. [77] [78] [79] Orexin neurons are regulated by ghrelin, 80 suggesting that there is a close relation between orexin and ghrelin in the brain with regard to the regulation of physiological functions. Further studies on the relationship between orexin and ghrelin in the central regulation of gut functions are needed.
Perspective
Here, we again stress our hypothesis that orexin A might be a trigger molecule involved in cephalic-phase gut stimulation. In addition, we propose that lack of orexin activity in the brain might contribute to the development of functional gastrointestinal disorders. Therefore, it is our hope that artifi cial control of orexinergic projection will lead to progress in the establishment of a novel therapeutic approach to the treatment of functional gastrointestinal disorders.
